Overview
Updated 14 Jul 2026
Brenda Sandmaier is Professor and Deputy Director, Translational Science and Therapeutics Division at Fred Hutchinson Cancer Center. The public record shows 670 publications with 36,879 citations (h-index 92), centered on Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia Research, Acute Lymphoblastic Leukemia research. It also documents an investigator role on 22 registered clinical trials, industry payments reported by 2 companies, 11 NIH-funded awards (1990–2025).
- Most recent indexed publication: 2026 · Blood
- Top research focus: Hematopoietic Stem Cell Transplantation
- 22 registered trials on ClinicalTrials.gov
- Open Payments reporting from 2 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 50 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 308.
Clinical & industrytrials, payments and federal funding
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 22 registered studies on ClinicalTrials.gov. The most recent:
- 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Sponsor: Fred Hutchinson Cancer Center
InvestigatorPhase 1/PHASE2RecruitingNCT03128034 - Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS
Sponsor: Fred Hutchinson Cancer Center
InvestigatorPhase 1CompletedNCT01300572 - Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
Sponsor: Fred Hutchinson Cancer Center
InvestigatorPhase 2CompletedNCT01252667
Industry payments
Updated 14 Jul 2026
2 companies reported payments to CMS in program years 2021–2022. These are public disclosures, not judgments. The latest:
- Apellis Pharmaceuticals, Inc.Program year20221 payment
- JAZZ PHARMACEUTICALS INC.Program year20211 payment
NIH funding
Updated 14 Jul 2026
11 NIH research awards on record, funded 1990–2025 per NIH RePORTER. The latest:
- Preventing Relapse After Non-myeloablative Stem Cell Transplantation: The Final Challenge
Fred Hutchinson Cancer Center
FY2025$2,074,913P01CA078902 - Project 2: Alpha-Emitter Radioimmunotherapy-Based Allografting to Cure Acute Leukemia and Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
FY2025$283,800P01CA078902
Congress activity
Updated 14 Jul 2026
32 congress contributions (2006–2024) across ASCO, ASH per OpenAlex. The most recent:
- Allogeneic Hematopoietic Cell Transplantation (HCT) for Adults with Acute Myeloid Leukemia Older Than Age 60
ASH Annual Meeting
ASH2024Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Comparative In Vitro Evaluation of Anti-HIV Immunotoxin, Antibody-Drug Conjugate, and Radioimmunoconjugate Targeted by the Same Antibody.
Antibodies (Basel, Switzerland)
2026 - Respiratory Virus Infections and Pulmonary Impairment After Allogeneic Hematopoietic Cell Transplantation.
The Journal of infectious diseases
2026
Most-cited worksby citation count (OpenAlex)
- 01
- 02
- 03Defining the Intensity of Conditioning Regimens: Working Definitions1,804 citations2009
- 04Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation1,480 citations2010
- 05
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
1100 Fairview Ave. N., P.O. Box 19024, Seattle, WA 98109-1024
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
- MD
University of Alberta
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗ - BSc
Genetics, University of Alberta
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
Editorial & leadership rolesjournal and society appointments
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
Awards & honorshonors on the public record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
Secondary affiliationsappointments beyond the home institution
- Professor
Division of Hematology and Oncology, University of Washington School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗ - Member
Immunotherapy Integrated Research Center (IIRC), Fred Hutch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗ - Affiliate Investigator
Clinical Research Division, Fred Hutch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
Media & interviewspress, podcasts and appearances
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →globenewswire.com ↗
- News feature: "ASTCT Names Brenda Sandmaier President"
ASH Clinical News (American Society of Hematology)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ashpublications.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- LinkedIn
linkedin.com/in/brenda-sandmaier-6b173639
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Brenda-Sandmaier-2
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - Doximity
doximity.com/pub/brenda-sandmaier-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Mentions by otherswhere others cite or feature them
- Other
fredhutch.org/en/news/center-news/2022/04/sandmaier-astct-presidency.html
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗ - LinkedIn
LinkedIn profile: "Brenda Sandmaier - Professor and Deputy Director of the Translational Science and Therapeutics Division"
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - ResearchGate
ResearchGate profile: "Professor (Full) and Deputy Director, Fred Hutch Cancer Center, Seattle"
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Lawrence Fong, MD
Fred Hutch Cancer Center
- 771
- publications
- 75
- h-index
- 9
- trials
Petros Grivas, MD, PhD
Fred Hutch Cancer Center
- 910
- publications
- 62
- h-index
- 6
- trials